 Stephen Frankel
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 8 | 2011 | 304 | 1.340 |
Why?
| | Lung Diseases | 5 | 2012 | 693 | 0.800 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2015 | 453 | 0.750 |
Why?
| | Vasculitis | 2 | 2012 | 73 | 0.660 |
Why?
| | Hospital Mortality | 2 | 2014 | 795 | 0.660 |
Why?
| | Critical Illness | 3 | 2017 | 657 | 0.640 |
Why?
| | Lung Diseases, Interstitial | 9 | 2015 | 469 | 0.600 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2012 | 22 | 0.470 |
Why?
| | Hospitals, Veterans | 1 | 2012 | 239 | 0.390 |
Why?
| | Wounds and Injuries | 2 | 2017 | 659 | 0.380 |
Why?
| | Cause of Death | 1 | 2012 | 369 | 0.370 |
Why?
| | Arteritis | 1 | 2010 | 27 | 0.370 |
Why?
| | Fibroblasts | 5 | 2011 | 839 | 0.360 |
Why?
| | Churg-Strauss Syndrome | 4 | 2018 | 18 | 0.350 |
Why?
| | Respiration, Artificial | 2 | 2017 | 540 | 0.350 |
Why?
| | Eosinophilia | 1 | 2011 | 190 | 0.340 |
Why?
| | Intensive Care Units | 1 | 2014 | 630 | 0.340 |
Why?
| | Respiratory Tract Diseases | 1 | 2010 | 141 | 0.330 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 121 | 0.320 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2008 | 84 | 0.310 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 5 | 0.300 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 24 | 0.300 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 29 | 0.300 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 101 | 0.280 |
Why?
| | Venous Thromboembolism | 1 | 2009 | 235 | 0.270 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2004 | 291 | 0.260 |
Why?
| | Exercise Therapy | 1 | 2009 | 352 | 0.260 |
Why?
| | Connective Tissue Diseases | 3 | 2013 | 57 | 0.250 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 145 | 0.250 |
Why?
| | Granulomatosis with Polyangiitis | 3 | 2018 | 42 | 0.250 |
Why?
| | Apoptosis | 4 | 2011 | 2433 | 0.230 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 94 | 0.230 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2005 | 1136 | 0.230 |
Why?
| | Antiviral Agents | 2 | 2021 | 655 | 0.230 |
Why?
| | Lung | 6 | 2014 | 3588 | 0.220 |
Why?
| | Precancerous Conditions | 1 | 2004 | 156 | 0.220 |
Why?
| | Adenoma | 1 | 2004 | 190 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 667 | 0.210 |
Why?
| | Smoking | 1 | 2009 | 1457 | 0.200 |
Why?
| | Humans | 33 | 2022 | 117053 | 0.200 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1771 | 0.190 |
Why?
| | Biomarkers | 1 | 2010 | 3549 | 0.170 |
Why?
| | Mycophenolic Acid | 2 | 2013 | 79 | 0.170 |
Why?
| | Diagnosis, Differential | 4 | 2011 | 1341 | 0.170 |
Why?
| | fas Receptor | 2 | 2011 | 98 | 0.160 |
Why?
| | Ganciclovir | 1 | 2017 | 49 | 0.150 |
Why?
| | Aged | 13 | 2017 | 19359 | 0.150 |
Why?
| | Middle Aged | 14 | 2018 | 27173 | 0.140 |
Why?
| | Interferon-gamma | 2 | 2013 | 732 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2017 | 145 | 0.140 |
Why?
| | Mutation | 3 | 2022 | 3420 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 5 | 2015 | 2403 | 0.130 |
Why?
| | Male | 17 | 2017 | 56665 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 182 | 0.130 |
Why?
| | Survival Rate | 4 | 2015 | 1679 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2017 | 673 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 81 | 0.110 |
Why?
| | Female | 16 | 2018 | 60635 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2018 | 674 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 271 | 0.110 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2011 | 10 | 0.100 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2011 | 9 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2004 | 2222 | 0.100 |
Why?
| | Pulmonary Eosinophilia | 1 | 2011 | 26 | 0.100 |
Why?
| | Pulmonary Alveoli | 2 | 2011 | 373 | 0.100 |
Why?
| | Respiratory Insufficiency | 2 | 2017 | 286 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2013 | 222 | 0.100 |
Why?
| | Sepsis | 1 | 2017 | 525 | 0.100 |
Why?
| | Rheumatic Diseases | 1 | 2011 | 49 | 0.100 |
Why?
| | Biopsy | 2 | 2014 | 1056 | 0.090 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 222 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2017 | 4507 | 0.090 |
Why?
| | Bronchoscopy | 1 | 2011 | 244 | 0.090 |
Why?
| | Antibodies, Antinuclear | 1 | 2009 | 56 | 0.080 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2009 | 25 | 0.080 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 20 | 0.080 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2009 | 41 | 0.080 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2015 | 58 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 337 | 0.080 |
Why?
| | Disease Progression | 2 | 2015 | 2467 | 0.080 |
Why?
| | Up-Regulation | 1 | 2011 | 837 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2008 | 281 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 328 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 993 | 0.070 |
Why?
| | Prognosis | 3 | 2009 | 3390 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2010 | 268 | 0.070 |
Why?
| | Pericardium | 1 | 2007 | 49 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1240 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 141 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1487 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2007 | 181 | 0.070 |
Why?
| | Cysts | 1 | 2007 | 94 | 0.070 |
Why?
| | Colectomy | 1 | 2007 | 84 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2011 | 3956 | 0.070 |
Why?
| | Rare Diseases | 1 | 2007 | 91 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2008 | 245 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2007 | 94 | 0.070 |
Why?
| | Autoantibodies | 1 | 2013 | 1332 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2007 | 132 | 0.070 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 16 | 0.070 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2006 | 35 | 0.070 |
Why?
| | Respiratory Function Tests | 3 | 2014 | 523 | 0.070 |
Why?
| | Wound Healing | 1 | 2008 | 269 | 0.070 |
Why?
| | Acute Disease | 1 | 2008 | 916 | 0.070 |
Why?
| | Heart Rate | 1 | 2009 | 708 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2010 | 12825 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 1949 | 0.060 |
Why?
| | Walking | 1 | 2009 | 420 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 76 | 0.060 |
Why?
| | Pleura | 1 | 2004 | 18 | 0.060 |
Why?
| | Colonoscopy | 1 | 2007 | 211 | 0.060 |
Why?
| | Proline | 1 | 2005 | 70 | 0.060 |
Why?
| | Vital Capacity | 2 | 2015 | 257 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 168 | 0.060 |
Why?
| | Hyperplasia | 1 | 2004 | 169 | 0.060 |
Why?
| | Echocardiography | 1 | 2007 | 564 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 115 | 0.060 |
Why?
| | Gene Expression | 2 | 2009 | 1466 | 0.060 |
Why?
| | Interleukin-4 | 1 | 2004 | 216 | 0.060 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 299 | 0.060 |
Why?
| | Cohort Studies | 2 | 2015 | 5051 | 0.060 |
Why?
| | Bleomycin | 1 | 2004 | 228 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2017 | 9257 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2377 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1657 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 391 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 825 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2633 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 525 | 0.050 |
Why?
| | Fibrosis | 1 | 2004 | 478 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 2951 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 125 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2480 | 0.050 |
Why?
| | Radiography | 1 | 2004 | 843 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 115 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2010 | 6454 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 50 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 354 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1458 | 0.050 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 85 | 0.050 |
Why?
| | Receptors, Virus | 1 | 2021 | 77 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 101 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 565 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 517 | 0.050 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 138 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1105 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2004 | 1993 | 0.040 |
Why?
| | Pneumonia | 1 | 2004 | 575 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 460 | 0.040 |
Why?
| | Cell Line | 3 | 2011 | 2670 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 298 | 0.040 |
Why?
| | Kinetics | 1 | 2021 | 1583 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 69 | 0.040 |
Why?
| | Mice | 4 | 2011 | 15309 | 0.040 |
Why?
| | Binding Sites | 1 | 2021 | 1206 | 0.040 |
Why?
| | Virus Activation | 1 | 2017 | 77 | 0.040 |
Why?
| | Risk Factors | 1 | 2009 | 8873 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 456 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2632 | 0.030 |
Why?
| | Adult | 4 | 2017 | 31003 | 0.030 |
Why?
| | Mice, Inbred C3H | 2 | 2005 | 240 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 1825 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1670 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 149 | 0.030 |
Why?
| | Length of Stay | 1 | 2017 | 989 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Microscopic Polyangiitis | 1 | 2012 | 13 | 0.030 |
Why?
| | Animals | 4 | 2011 | 32737 | 0.030 |
Why?
| | Necrosis | 1 | 2012 | 223 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 60 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 131 | 0.020 |
Why?
| | Alanine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
| | Threonine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
| | Elastin | 1 | 2009 | 77 | 0.020 |
Why?
| | Oximetry | 1 | 2009 | 80 | 0.020 |
Why?
| | Myoblasts | 1 | 2009 | 74 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 339 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 513 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2007 | 64 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 877 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 423 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 541 | 0.020 |
Why?
| | Medical Records | 1 | 2006 | 159 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2005 | 70 | 0.020 |
Why?
| | Asparagine | 1 | 2005 | 30 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 639 | 0.020 |
Why?
| | COS Cells | 1 | 2005 | 179 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2005 | 168 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2648 | 0.020 |
Why?
| | Serine | 1 | 2005 | 130 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1588 | 0.020 |
Why?
| | Growth Substances | 1 | 2004 | 133 | 0.020 |
Why?
| | Cytoplasm | 1 | 2005 | 269 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 106 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2005 | 352 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 1877 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 150 | 0.010 |
Why?
| | Th2 Cells | 1 | 2004 | 164 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2009 | 940 | 0.010 |
Why?
| | Cell Communication | 1 | 2004 | 278 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 818 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 406 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2515 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3099 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2236 | 0.010 |
Why?
| | Cell Membrane | 1 | 2005 | 681 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1030 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1590 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 615 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 6389 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 10675 | 0.010 |
Why?
| | Adolescent | 1 | 2009 | 18215 | 0.010 |
Why?
|
|
Frankel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|